Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-T Cell Therapy for Acute Myeloid Leukemia
NCT06904859Phase 1Completed
- Sponsor
- Shenzhen University General Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Shenzhen University General Hospital TCR-T cells in acute myeloid leukemia (AML), sponsored by Shenzhen University General Hospital. Primary endpoint: Decreased AML percentage in blood at 20 days. Started Jan 2019; status: completed.
02
Drugs
Shenzhen University General Hospital TCR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06904859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904859.